1. Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC). (December 2016) Authors: Tijeras-Raballand, A.; Le Bitoux, M.A.; Maillard, A.; Albuquerque, M.; Colnot, N.; Barral, M.; Dohan, A.; Bonnin, P.; Pocard, M.; Benhadji, K.; Paradis, V.; Raymond, E.; Harari, A.; Faivre, S.; De Gramont, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗